Obagi Medical Introduces New Lip Therapy Protocol Designed to Resurface, Replenish, and Protect
MWN-AI** Summary
Obagi Medical, a pioneer in advanced skincare and part of Waldencast plc (NASDAQ: WALD), has launched a pioneering Lip Therapy Protocol to enhance lip care and protection. This innovative two-step regimen comprises the Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and the Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30, designed to rejuvenate and protect one of the face’s most delicate areas.
The protocol focuses on nightly rejuvenation and daily protection, utilizing a combination of advanced formulations to resurface the lips while restoring hydration. The Smoothing Micro-Peel employs three resurfacing acids, including Glycolic, Lactic, and Gluconolactone, to gently exfoliate the lips. It incorporates Hyaluronic Acid, which retains moisture, and Argan Oil for a softer, youthful appearance. This first step aims to enhance the effectiveness of the subsequent treatment.
Following this, the Soothe & Protect Lip Treatment SPF 30 offers daily hydration and broad-spectrum sun protection. Enriched with a plumping peptide complex, Calendula, and Vitamin E, this treatment addresses fine lines and fortifies the lip barrier against UV exposure.
In consumer studies, users reported visible improvements in lip texture and hydration shortly after application, with ongoing benefits observed over two weeks. Dr. Suzan Obagi highlighted the vulnerability of lips to environmental damage, arguing that this dual protocol provides a comprehensive solution for maintaining smoother, healthier lips.
Priced at $55 for the Micro-Peel and $40 for the Lip Treatment, the new products reflect Obagi's ongoing commitment to scientifically validated skincare solutions. Both products are available through professional channels and on Obagi's website as of February 3, 2026.
MWN-AI** Analysis
Obagi Medical's recent introduction of its Lip Therapy Protocol signifies a strategic expansion into a niche yet lucrative segment of the skincare market. This two-step regimen, consisting of the AHA + PHA Smoothing Micro-Peel and Soothe & Protect Lip Treatment SPF 30, aligns with the evolving consumer preferences for specialized, high-quality skincare products that address specific concerns, such as dryness and environmental damage.
From a financial perspective, this launch presents a compelling opportunity for investors. As the fastest-growing professional skincare brand in the U.S. as of 2024, Obagi Medical, under Waldencast plc (NASDAQ: WALD), is well-positioned to capitalize on the growing demand for effective lip care solutions. The current valuation of Waldencast should be closely monitored, especially given the potential for revenue growth driven by these innovative offerings.
Furthermore, the clinical validation and dermatologist endorsements referenced in the announcement enhance the credibility of the products, likely boosting consumer trust and encouraging trial and adoption. This science-backed approach can create a competitive advantage in a crowded market, further solidifying Obagi's brand equity.
Investors should consider analyzing retail partnerships, particularly how the company plans to leverage its existing distribution channels to optimize market outreach. The capability to convert professional endorsements into consumer purchases will be critical. It is also important to assess consumer reception following the launch, with metrics such as sales growth and customer feedback indicating the potential for long-term brand loyalty.
Overall, investors should keep an eye on Waldencast's broader strategy for scaling its portfolio while maintaining brand integrity, as this could provide significant insights into its future growth trajectory and stock performance. A focus on innovation and consumer trends bodes well for Obagi Medical's prospects in the skincare market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), continues its commitment to advanced skin science with the launch of two new lip innovations designed to work together as a targeted treatment protocol: Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30.
Building on the brand’s legacy of clinically backed solutions for skin health and rejuvenation, the new Lip Therapy protocol brings Obagi’s expertise to one of the most delicate areas of the face. Designed for nightly rejuvenation and daily protection, the two-step regimen gently resurfaces the lips while restoring hydration, improving texture, and defending against environmental stressors, including the sun’s UV rays.
“This exciting new launch reflects Obagi’s long-standing approach to skincare innovation,” said Justin Giouzepis, Chief Marketing Officer. “Thoughtful formulation and clinical validation come together in a dermatologist-tested lip protocol that delivers visible smoothing while remaining gentle enough for everyday use.”
The Lip Therapy AHA + PHA Smoothing Micro-Peel is a gentle no-scrub, chemical exfoliating treatment formulated with 3 resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone to resurface and smooth the delicate lip surface. Hyaluronic Acid, a multi-molecular glycerin system, and Argan Oil help lock in moisture and support a softer, smoother, more youthful-looking appearance. Designed as the first step in the regimen, the Micro-Peel visibly smooths texture and can help enhance the performance of subsequent treatments.
Following resurfacing, Soothe & Protect Lip Treatment SPF 30 delivers daily hydration, comfort, and broad-spectrum sun protection. Formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E, the treatment visibly smooths fine lines while supporting the lip barrier and protecting against UVA and UVB exposure. Its comforting, replenishing formula makes it ideal for everyday use.
In consumer perception testing, when used as part of the complete protocol, the vast majority of users reported their lips looked and felt smoother, plumper, and more replenished immediately after application, with continued improvements in hydration, fine lines, and overall lip appearance in just two weeks.1
“Lips are uniquely vulnerable to environmental damage and dehydration, especially following in-office treatments or the application of wrong topical products,” said Dr. Suzan Obagi, Chief Medical Director. “This two-step protocol addresses both rejuvenation and protection, helping patients maintain smoother, healthier-looking lips with clinically thoughtful ingredients they can trust.”
Together, the Lip Therapy AHA + PHA Smoothing Micro-Peel and Soothe & Protect Lip Treatment SPF 30 reinforce Obagi Medical’s philosophy that skin health is a long-term investment, extending targeted, professional-grade care to deliver visible, science-backed results where they matter most.
Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40) are now available through partnering professional channels. They will be available for customers to purchase on Obagi.com beginning February 3rd
*Consumer perception study results on file. Results may vary.
1. Data on file at Obagi Cosmeceuticals LLC. Results may vary.
2. Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/424b9e84-977f-45a5-bb68-c9e06e9d6e29
FAQ**
How will the launch of Obagi's new lip innovations impact the market positioning of Waldencast Acquisition Corp. WALD in the competitive skincare industry?
What strategies does Waldencast Acquisition Corp. WALD plan to implement to leverage the sales from the new Obagi Lip Therapy products in 2026?
Can we expect further expansion of the Obagi brand within the Waldencast Acquisition Corp. WALD portfolio following the success of these new lip treatments?
How does the latest product launch correlate with Waldencast Acquisition Corp. WALD’s long-term growth strategy in the beauty and wellness market?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-1.91% G/L:
$1.54 Last:
19,807 Volume:
$1.54 Open:
